Advancing the use of digital health technologies (DHTs) in clinical investigations is a priority for the agency, three FDA staff members reiterated in an April 11 JAMA Health Forum Viewpoint. “The FDA believes DHTs are reshaping the world of clinical trials,” the article said. The authors from the Center for Drug Evaluation and Research’s Office of Medical Policy and Office o... Read More